Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics
Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.
Sphere Fluidics has announced an investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf, for reliable and highly stable droplet generation and processing. Sphere Fluidics will expand operations to meet demand for large-scale commercial supply of its high-performing surfactant for use in a wide range of microfluidic application workflows.
Pico-Surf is a high-quality and animal-origin-free biocompatible surfactant optimized to support the formation of aqueous solution-in-oil picodroplets. Sphere Fluidics aims to increase production of Pico-Surf by three-fold in 2020, while maintaining its industry-leading standards, through significant investment of resources in manufacture and quality control processes, and workforce. As part of the company's range of specialist chemicals, Pico-Surf is designed to work effectively and flexibly across a broad range of microfluidic systems, including the Sphere Fluidics' proprietary single cell analysis platforms and applications, such as molecular biology assays, cell secretion assays and cell growth studies.
The unique and patented molecular structure of Pico-Surf stabilizes droplets, and retains and protects their cellular and molecular contents over a wide range of temperatures and biological conditions, helping to ensure high cell viability for improved assay performance. Droplets generated using Pico-Surf show low end point interfacial tension and critical micelle concentration in comparison to other commercially available surfactants. The purity and quality of the surfactant also enables a more efficient droplet sorting process at low voltage. The ready-to-use surfactant is available in large batches or made-to-order with ensured lot-to-lot consistency.
Dr Marian Rehak, Vice President of Research and Development, Sphere Fluidics, said: “We are enthused by the increased demand for Pico-Surf, and eager to mobilize its production to meet demand. While doing so, we will ensure its very high-quality control standards are maintained, meaning researchers can continue to rely on Pico-Surf to create droplets that are stable and reproducible.”
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Sphere Fluidics’ world-leading expertise in picodroplet technology has enabled the development of an ever-growing range of high-performing patented consumables, vital for the successful use of microfluidic systems. All our consumable products have been designed to be platform-agnostic, so they work effectively with a number of microfluidic systems.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...